Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2013

01-12-2013 | NON-THEMATIC REVIEW

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation

Authors: Sara De Dosso, Enrique Grande, Jorge Barriuso, Daniel Castellano, Josep Tabernero, Jaume Capdevila

Published in: Cancer and Metastasis Reviews | Issue 3-4/2013

Login to get access

Abstract

The molecular events of tumorigenesis in neuroendocrine tumors are poorly understood. Understanding of the molecular alterations will lead to the identification of molecular markers, providing new targets for therapeutics. The purpose of this review was to critically analyze the genetic abnormalities in neuroendocrine tumors, with the aim of identifying biomarkers that indicate a response to agents developed against these targets and to serve as an understanding for the combinations of different active compounds. Human epidermal growth factor receptor 1/2 (EGFR and HER2), vascular endothelial growth factor receptors, hepatocyte growth factor receptor (c-Met), platelet-derived growth factor receptor, insulin-like growth factor, phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin pathway, and heat shock proteins are all interesting candidate biomarkers with involvement in carcinogenesis and tumor evolution of several neoplasms, including neuroendocrine tumors. Some of them have already been evaluated both as targets and also as biomarkers in clinical trials conducted in advanced neuroendocrine tumor settings, and others should encourage further investigations into innovative therapeutic opportunities.
Literature
1.
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., et al. (2008). One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology, 26, 3063–3072.PubMedCrossRef
2.
Modlin, I. M., Lye, K. D., & Kidd, M. (2003). A 5-decade analysis of 13715 carcinoid tumors. Cancer, 97, 934–959.PubMedCrossRef
3.
DeLellis, R. A. (2001). The neuroendocrine system and its tumors. American Journal of Clinical Pathology, 115, S5.PubMed
4.
Grande, E., Capdevila, J., Barriuso, J., Anton-Aparicio, J., & Castellano, D. (2012). Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist? Cancer Metastasis Reviews, 31(1-2), 47–53.PubMedCrossRef
5.
Castellano, D., Salazar, R., & Raymond, E. (2011). Future perspectives on neuroendocrine tumors. Cancer Metastasis Reviews, 30(Suppl 1), 35–40.PubMed
6.
Grozinsky-Glasberg, S., Shimon, I., & Rubinfeld, H. (2012). The role of cell lines in the study of neuroendocrine tumors. Neuroendocrinology, 96, 173–187.PubMedCrossRef
7.
Arany, I., Rady, P., Evers, B. M., Tyring, S. K., & Townsend, C. M. (1994). Analysis of multiple molecular changes in human endocrine tumors. Surgical Oncology, 3(3), 153–159.PubMedCrossRef
8.
Zitzmann, K., De Toni, E. N., Brand, S., Göke, B., Meinecke, J., Spöttl, G., et al. (2007). The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology, 85(1), 54–60.PubMedCrossRef
9.
Pitt, S. C., Chen, H., & Kunnimalaiyaan, M. (2009). Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Annals of Surgical Oncology, 16(10), 2936–2942.PubMedCrossRef
10.
Kölby, L., Bernhardt, P., Ahlman, H., Wängberg, B., Johanson, V., Wigander, A., et al. (2001). A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. American Journal of Pathology, 158(2), 745–755.PubMedCrossRef
11.
Zitzmann, K., Rüden, J., Brand, S., Göke, B., Lichtl, J., Spöttl, G., & Auernhammer, C. J. (2010). Compensatory activation of Akt in response to mTOR and Raf inhibitors—a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Letter, 295(1), 100–109.CrossRef
12.
Hanahan, D. (1985). Heritable formation of pancreatic beta-cell tumors in trasngenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature, 315, 115–122.PubMedCrossRef
13.
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation, 111(9), 1287–1295.PubMed
14.
Kitadai, Y., Sasaki, T., Nakamura, T., Bucana, C. D., & Fidler, I. J. (2006). Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth ad metastasis of human colon carcinoma. American Journal of Pathology, 169, 2054–2065.PubMedCrossRef
15.
Kaplan, C. D., Kruger, J. A., Zhou, H., Luo, Y., Xiang, R., & Reisteld, R. A. (2006). A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine, 24, 6994–7002.PubMedCrossRef
16.
Chiu, C. W., Nozawa, H., & Hanahan, D. (2010). Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. Journal of Clinical Oncology, 28(29), 4425–4433.PubMedCrossRef
17.
Rinke, A., Müller, H. H., Schade-Brittinger, C., Klose, K. J., Barth, P., Wied, M., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27(28), 4656–4663.PubMedCrossRef
18.
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364(6), 514–523.PubMedCrossRef
19.
Raymond, E., Dahan, L., Raoul, J. L., Bang, Y. J., Borbath, I., Lombard-Bohas, C., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364(6), 501–513.PubMedCrossRef
20.
Naraev, B., Strosberg, J. R., & Halfdanarson, T. R. (2012). Current status and perspectives of targeted therapy in well differentiated neuroendocrine tumors. Oncology, 83, 117–127.PubMedCrossRef
21.
Kulke, M. H., Hornick, J. L., Frauenhoffer, C., Hooshmand, S., Ryan, D. P., Enzinger, P. C., et al. (2009). O 6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clinical Cancer Research, 15(1), 338–345.PubMedCrossRef
22.
Shah, T., Hochhauser, D., Frow, R., Quaglia, A., Dhillon, A. P., & Caplin, M. E. (2006). Epidermal growth factor receptor expression and activation in neuroendocrine tumours. Journal of Neuroendocrinology, 18(5), 355–360.PubMedCrossRef
23.
Srivastava, A., Alexander, J., Lomakin, I., & Dayal, Y. (2001). Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors. Human Pathology, 32(11), 1184–1189.PubMedCrossRef
24.
Gilbert, J. A., Adhikari, L. J., Lloyd, R. V., Rubin, J., Haluska, P., Carboni, J. M., et al. (2010). Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocrine-Related Cancer, 17(3), 623–636.PubMedCrossRef
25.
Rickman, O. B., Vohra, P. K., Sanyal, B., Vrana, J. A., Aubry, M. C., Wigle, D. A., et al. (2009). Analysis of ErbB receptors in pulmonary carcinoid tumors. Clinical Cancer Research, 15(10), 3315–3324.PubMedCrossRef
26.
Tannapfel, A., Vomschloss, S., Karhoff, D., Markwarth, A., Hengge, U. R., Wittekind, C., et al. (2005). BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. American Journal of Clinical Pathology, 123(2), 256–260.PubMedCrossRef
27.
Hobday, T. J., Holen, K., Donehower, R., Camoriano, J., Kim, G., Picus, J., et al. (2006). A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. ASCO Meeting Abstracts, 24(18), 4043.
28.
Azzoni, C., Bottarelli, L., Cecchini, S., Lagrasta, C., Pizzi, S., D’Adda, T., et al. (2011). Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors. Virchows Archiv, 458(5), 525–536.PubMedCrossRef
29.
Hansel, D. E., Rahman, A., House, M., Ashfaq, R., Berg, K., Yeo, C. J., et al. (2004). Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clinical Cancer Research, 10(18 Pt 1), 6152–6158.PubMedCrossRef
30.
Peghini, P. L., Iwamoto, M., Raffeld, M., Chen, Y. J., Goebel, S. U., Serrano, J., et al. (2002). Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clinical Cancer Research, 8(7), 2273–2285.PubMed
31.
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., et al. (2012). Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discovery, 2(3), 270–287.PubMedCrossRef
32.
Wulbrand, U., Remmert, G., Zofel, P., Wied, M., Arnold, R., & Fehmann, H. C. (2000). mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. European Journal of Clinical Investigation, 30(8), 729–739.PubMedCrossRef
33.
Hopfner, M., Baradari, V., Huether, A., Schofl, C., & Scherubl, H. (2006). The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocrine-Related Cancer, 13(1), 135–149.PubMedCrossRef
34.
Tolcher, A. W., Sarantopoulos, J., Patnaik, A., Papadopoulos, K., Lin, C. C., Rodon, J., et al. (2009). Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. Journal of Clinical Oncology, 27(34), 5800–5807.PubMedCrossRef
35.
Fjallskog, M. L., Lejonklou, M. H., Oberg, K. E., Eriksson, B. K., & Janson, E. T. (2003). Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clinical Cancer Research, 9(4), 1469–1473.PubMed
36.
Corbo, V., Beghelli, S., Bersani, S., Antonello, D., Talamini, G., Brunelli, M., et al. (2012). Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Annals of Oncology, 23(1), 127–134.PubMedCrossRef
37.
Bukowski, R. M., Eisen, T., Szczylik, C., Stadler, W. M., Simantov, R., Shan, M., et al. (2007). Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. ASCO Meeting Abstracts, 25(18), 5023.
38.
Mass, R. D., Sarkar, S., Holden, S. N., & Hurwitz, H. (2005). Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts, 23(16), 3514.
39.
Terris, B., Scoazec, J. Y., Rubbia, L., Bregeaud, L., Pepper, M. S., Ruszniewski, P., et al. (1998). Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology, 32(2), 133–138.PubMedCrossRef
40.
La Rosa, S., Uccella, S., Finzi, G., Albarello, L., Sessa, F., & Capella, C. (2003). Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Human Pathology, 34(1), 18–27.PubMedCrossRef
41.
Oxboel, J., Binderup, T., Knigge, U., & Kjaer, A. (2009). Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors. Oncology Reports, 21(3), 769–775.PubMed
42.
Kulke, M. H., Lenz, H. J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., et al. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 26(20), 3403–3410.PubMedCrossRef
43.
Bello, C., Deprimo, S. E., Friece, C., Smeraglia, J., Sherman, L., Tye, L., et al. (2006). Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. ASCO Meeting Abstracts, 24(18), 4045.
44.
Garcia-Donas, J., Esteban, E., Leandro-Garcia, L. J., Castellano, D. E., del Alba, A. G., Climent, M. A., et al. (2011). Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. The Lancet Oncology, 12(12), 1143–1150.PubMedCrossRef
45.
Yao, J. C. (2007). Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Practice & Research. Clinical Endocrinology & Metabolism, 21(1), 163–172.CrossRef
46.
Missiaglia, E., Dalai, I., Barbi, S., Beghelli, S., Falconi, M., della Peruta, M., et al. (2010). Pancreatic endocrine tumors: expression profiling evidences a role for AKT–mTOR pathway. Journal of Clinical Oncology, 28(2), 245–255.PubMedCrossRef
47.
Corbo, V., Dalai, I., Scardoni, M., Barbi, S., Beghelli, S., Bersani, S., et al. (2010). MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocrine-Related Cancer, 17(3), 771–783.PubMedCrossRef
48.
Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., et al. (2011). DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 331(6021), 1199–1203.PubMedCrossRef
49.
Shida, T., Kishimoto, T., Furuya, M., Nikaido, T., Koda, K., Takano, S., et al. (2010). Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemotherapy and Pharmacology, 65(5), 889–893.PubMedCrossRef
50.
Righi, L., Volante, M., Rapa, I., Tavaglione, V., Inzani, F., Pelosi, G., et al. (2010). Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocrine-Related Cancer, 17(4), 977–987.PubMedCrossRef
51.
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Horsch, D., Winkler, R. E., et al. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet, 378(9808), 2005–2012.PubMedCrossRef
52.
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., et al. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95(9), 1148–1154.PubMedCrossRef
53.
Cho, D., Signoretti, S., Dabora, S., Regan, M., Seeley, A., Mariotti, M., et al. (2007). Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clinical Genitourinary Cancer, 5(6), 379–385.PubMedCrossRef
54.
Delbaldo, C., Albert, S., Dreyer, C., Sablin, M. P., Serova, M., Raymond, E., et al. (2011). Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Targeted Oncology, 6(2), 119–124.PubMedCrossRef
55.
Roldo, C., Missiaglia, E., Hagan, J. P., Falconi, M., Capelli, P., Bersani, S., et al. (2006). MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. Journal of Clinical Oncology, 24(29), 4677–4684.PubMedCrossRef
56.
Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 103(7), 2257–2261.PubMedCrossRef
57.
Svejda, B., Kidd, M., Kazberouk, A., Lawrence, B., Pfragner, R., & Modlin, I. M. (2011). Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer, 117(18), 4141–4154.PubMedCrossRef
58.
Vilar, E., Salazar, R., Perez-Garcia, J., Cortes, J., Oberg, K., & Tabernero, J. (2007). Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer, 14(2), 221–232.PubMedCrossRef
59.
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., et al. (2008). Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. Journal of Clinical Oncology, 26(10), 1603–1610.PubMedCrossRef
60.
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., et al. (2008). Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology, 26(26), 4311–4318.PubMedCrossRef
61.
Yao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., et al. (2010). Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology, 28(1), 69–76.PubMedCrossRef
62.
De Vries, E., Anthony, L. B., Sideris, L., Chen, L., Lebrec, J., Tsuchihashi, Z., et al. (2011). Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): phase III RADIANT-3 Study results. ASCO Meeting Abstracts, 29(15_Suppl), 10624.
63.
Yao, J. C., Ricci, S., Winkler, R. E., Jehl, V., & Pavel, M. E. (2011). Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): updated safety and efficacy results from RADIANT-2. ASCO Meeting Abstracts, 29(15_Suppl), 4011.
64.
Yao, J. C., Phan, A. T., Fogleman, D., Ng, C. S., Jacobs, C. B., Dagohoy, C. D., et al. (2010). Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. ASCO Meeting Abstracts, 28(15_Suppl), 4002.
65.
Yao, J. C., Phan, A., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S. C., et al. (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Journal of Clinical Oncology, 26(8), 1316–1323.PubMedCrossRef
66.
Ng, C. S., Charnsangavej, C., Wei, W., & Yao, J. C. (2011). Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR. American Journal of Roentgenology, 196(3), 569–576.PubMedCrossRef
67.
Ng, C. S., Wang, X., Faria, S. C., Lin, E., Charnsangavej, C., & Tannir, N. M. (2010). Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR. American Journal of Roentgenology, 194(1), 166–171.PubMedCrossRef
68.
Phan, A. T., Yao, J. C., Fogelman, D. R., Hess, K. R., Ng, C. S., Bullock, S. A., et al. (2010). A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). ASCO Meeting Abstracts, 28(15_Suppl), 4001.
69.
Cui, T., Hurtig, M., Elgue, G., Li, S. C., Veronesi, G., Essaghir, A., et al. (2010). Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One, 5(12), e16010.PubMedCrossRef
70.
Khan, M. S., Tsigani, T., Rashid, M., Rabouhans, J. S., Yu, D., Luong, T. V., et al. (2011). Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clinical Cancer Research, 17(2), 337–345.PubMedCrossRef
Metadata
Title
The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation
Authors
Sara De Dosso
Enrique Grande
Jorge Barriuso
Daniel Castellano
Josep Tabernero
Jaume Capdevila
Publication date
01-12-2013
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-013-9421-0

Other articles of this Issue 3-4/2013

Cancer and Metastasis Reviews 3-4/2013 Go to the issue

NON-THEMATIC REVIEW

Central and peripheral nervous systems: master controllers in cancer metastasis

Erratum

Erratum to: The role of FOXP3 in the development and metastatic spread of breast cancer

NON-THEMATIC REVIEW

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

OriginalPaper

Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos

EditorialNotes

Preface

OriginalPaper

Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits